Tue Sep 10 14:00:00 UTC 2024: ## Gene Therapy Shows Promise in Restoring Vision for Patients with Inherited Blindness

**Cranbury, NJ** – A new gene therapy, ATSN-101, has demonstrated significant potential in restoring vision for patients suffering from Leber congenital amaurosis 1 (LCA1), a severe form of inherited blindness. This groundbreaking result comes from a Phase 1/2 clinical trial, showing a robust safety profile and remarkable visual improvement in patients with LCA1 caused by mutations in the GUCY2D gene.

The study, conducted at multiple sites across the United States, involved 15 patients with genetically confirmed LCA1. They received subretinal injections of ATSN-101, a gene therapy specifically designed to target the GUCY2D gene, which is responsible for up to 20% of LCA cases.

The results, published in [Insert journal/conference name], are highly encouraging. Patients receiving the high dose of ATSN-101 experienced an average improvement of 20 decibels (dB) in their dark-adapted full-field stimulus test (FST), signifying a 100-fold improvement in vision. Two patients even showed a staggering 40 dB improvement, representing a 10,000-fold improvement in their ability to see.

“This is a major step forward in the fight against inherited blindness,” said Dr. Artur Cideciyan, lead researcher and co-director of the Center for Hereditary Retinal Degeneration at the University of Pennsylvania Perelman School of Medicine. “We are excited to see that this gene therapy not only demonstrates safety but also achieves significant visual improvement in patients who have lived with severe vision loss for many years.”

While the trial is still ongoing, these initial findings offer a glimmer of hope for individuals with LCA1 and other inherited retinal diseases. With the only gene therapy specifically targeting LCA1 currently under investigation, ATSN-101 could potentially change the lives of countless patients struggling with this devastating condition.

Read More